SlideShare ist ein Scribd-Unternehmen logo
1 von 28
ACTIVE
PHARMACEUTICAL
INGREDIENTS
“CARVEDILOL”
VINOTHARAN NAIR(1000024)
SANGIDHA JAGATHEESAN(1000013 )
CONTENTS
 Introduction
 History
 Structure of Carvedilol
 Properties of Carvedilol
 Uses of Carvedilol
 How its‟s works ??
 Why Carvedilol is preferred ??
 Common Side Effects
 Manufacturing Process
 SHE Considerations
 Price aspect
 Market Demand Vs. Supply
INTRODUCTION
Carvedilol also known as Coreg
Used commonly in the treatment of CHF
or Congestive Heart failure or high blood
pressure
Carvedilol is a nonselective beta
blocker/alpha-1 blocker indicated in the
treatment of mild to severe congestive
heart failure (CHF)
HISTORY
Carvedilol was discovered by Robert R.
Ruffolo
The discovery and development of
carvedilol encountered an adverse
regulatory climate, skepticism by the
cardiology community and hesitance by
the company, and in the early 1990s
The fate of the drug was uncertain
 Robert R Ruffolo was President of Research and
Development for Wyeth Pharmaceuticals, and
corporate Senior Vice President of Wyeth from 2001
to 2008

Robert R Ruffolo
STRUCTURE OF “CARVEDILOL”

2D view

3D view
 The trade name of Carvedilol is known as Coreg
 This tablet is oval in shape and white colored
 It contains differing concentrations
of Carvedilol namely in 3.125, 6.25, 12.5 and 25 m
dosages.
 Molecular Formula: C 24 H 26 N 2 O 4

Carvedilol in tablet form
PROPERTIES OF “CARVEDILOL”
These active pharmaceutical ingredients can
be dissolved in water, intestinal fluids or
gastric fluids
Carvedilol should be taken with food
USES OF “CARVEDILOL”
Carvedilol is used for treating high blood
pressure and congestive heart failure.
It is also used after a heart attack to improve
the chance of survival if your heart is not
pumping well
To treat a certain type of irregular heartbeat
Carvedilol also helps to relax blood
vessels, reduces the need for oxygen in the
body, and helping the heart beat more
regularly and efficiently
HOW IT WORKS ??
Most norepinephrine reactants will activate
nerve endings, which control heart muscle
movements
Carvedilol drug works by blocking the binding
of the norepinephrine to these receptors
 This way, the heart rhythm slows down and
the pumping force of the heart muscles is also
reduced
WHY “CARVEDILOL” IS PREFERRED??
Carvedilol does not worsen existing heart
failure symptoms like some other drugs do
Compared to other drugs, which work in a
similar fashion, Carvedilol does not have
much inotropic effects or inverse agonist
effects
However, there is no scientific evidence to
support the fact that Carvedilol is more
preferred compared to other beta blocking
drugs
COMMON SIDE EFFECTS:
The most common side effects include:
Dizziness
Fatigue
Hypotension
Diarrhea
Weight gain
SIDE EFFECTS IF YOU DISCONTINUE THE
CONSUMPTION OF „CARVEDILOL‟
Sharp chest pain
Irregular heartbeat
Sometimes heart attack
MANUFACTURING PROCESS OF
“CARVEDILOL”
The manufacture of products based on small molecule Active Pharmaceutical Ingredients
(API) remains critical to global healthcare
 The manufacturing landscape is also full of
challenges and opportunities
This is due to emerging international markets
and rapidly evolving
social, economic, regulatory and
environmental expectations
SIFTING
Sift Carvedilol through , Lactose
monohydrate and Ferric Oxide
through the above sifted Carvedilol
and Lactose monohydrate it is
sifted with Ferric Oxide through
Lactose monohydrate and
Microcrystalline Cellulose.
DRY MIXING
Load the above sifted material in Rapid mixer
granulator and mix for 10 minutes with
impeller slow speed.

GRANULATING
 Add binder solution over dry mix material in a
period of 10 minutes at impeller slow speed
and mix the content in Rapid Mixer Granulator
at impeller slow speed.
DRYING
Air dry the wet mass for 10 minutes and
dry at inlet temperature to reach NMT
80°C, dry the granules till loss on drying
reaches to not more than 105°C.
SIFTING AND MILLING
Sift the dried granules and mill
retentions through multimill using 1mm
screen at medium speed and knives
forward configuration. Sifting of extra
granular Materials; Sift Silica Colloidal
Anhydrous and Magnesium Stearate.
BLENDING AND LUBRICATION
 Mix the materials of dried granules with Silica
Colloidal Anhydrous in Octagonal Blender for
15 minutes. Add Magnesium Stearate to the
above materials in Octagonal Blender for 5
minutes.
THE PROCESS
FLOWCHART
RAPID MIXER GRANULATOR
SHE Consideration
SAFETY CONSIDERATION
 Reduce direct skin contact, reduce exposure via
inhalation; and minimize the possibility of chemicals
being brought home on workers‟ clothing
 As with all potentially hazardous
exposures, protective measures should include:
engineering controls (e.g., barriers and
containments, laboratory hoods, glove boxes, and
worker isolation);
 Administrative controls; personal protective
equipment (e.g., respirators, gloves and lab coats)
 Training
HEALTH CONSIDERATION
Hazardous exposure to workers may occur
through inhalation of dust created during:
hand manipulation
operation of a tablet encapsulation machine
by performing sieving and granulation
operations
PRICE ASPECT OF THIS PROCESS
 Chronic heart failure (CHF) is now recognized as a
major and escalating public health problem.
 The costs of this syndrome, both in economic and
personal terms, are considerable.
 The prevalence of CHF is 1–2% and appears to be
increasing, in part because of ageing of the
population.
 60 tablets of carvedilol of 25mg would be $4.00
MARKET DEMAND VS. SUPPLY
 Manufacture and market Carvedilol Tablets, 3.125
mg, 6.25 mg, 12.5, and 25 mg. The Office of Generic
Drugs, U.S. Food and Drug Administration, has
determined the Ranbaxy formulations to be
bioequivalent and have the same therapeutic effect
as that of the reference listed drug Coreg®
Tablets, 3.125 mg, 6.25 mg, 12.5 mg, and 25
mg, respectively.
 Total annual market sales for Carvedilol Tablets were
$1.6 billion (IMS – MAT: June 2007).
REFERENCES
http://eurjhf.oxfordjournals.org/content/ 3/3/283.full
http://www.goodrx.com/coreg/price
http://www.aafp.org/afp/1998/1101/p1627.html
http://www.ranbaxy.com/ranbaxy -gains-us-fda-approval-tomanufacture-and-market-carvedilol-tablets-in-the-us-market
 http://en.wikipedia.org/wiki/Norepinephrine /





Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Anticholinergic agent
Anticholinergic agentAnticholinergic agent
Anticholinergic agent
 
ACE inhibitors drugs
ACE inhibitors drugsACE inhibitors drugs
ACE inhibitors drugs
 
Antihyperlipidemic drug
Antihyperlipidemic drugAntihyperlipidemic drug
Antihyperlipidemic drug
 
Sympathomimetic Drugs
Sympathomimetic Drugs Sympathomimetic Drugs
Sympathomimetic Drugs
 
Adrenergic & cholinergic in Medicinal Chemistry
Adrenergic & cholinergic in Medicinal Chemistry Adrenergic & cholinergic in Medicinal Chemistry
Adrenergic & cholinergic in Medicinal Chemistry
 
Adrenergic agonist antagonist
Adrenergic agonist antagonistAdrenergic agonist antagonist
Adrenergic agonist antagonist
 
Pharmacotherapy of Heart Failure
Pharmacotherapy of Heart FailurePharmacotherapy of Heart Failure
Pharmacotherapy of Heart Failure
 
sedative and hypnotics
sedative and hypnotics sedative and hypnotics
sedative and hypnotics
 
Warfarin
WarfarinWarfarin
Warfarin
 
Salbutamol
SalbutamolSalbutamol
Salbutamol
 
2nd unit anti-hypertensive agents ppt
2nd unit anti-hypertensive agents ppt2nd unit anti-hypertensive agents ppt
2nd unit anti-hypertensive agents ppt
 
Calcium Channel Blockers
Calcium Channel Blockers Calcium Channel Blockers
Calcium Channel Blockers
 
Gastric Proton pump inhibitors
Gastric Proton pump inhibitorsGastric Proton pump inhibitors
Gastric Proton pump inhibitors
 
Diuretics
DiureticsDiuretics
Diuretics
 
H1and h2 receptors
H1and h2 receptorsH1and h2 receptors
H1and h2 receptors
 
Anti hyperlipidemic agents
Anti hyperlipidemic agentsAnti hyperlipidemic agents
Anti hyperlipidemic agents
 
Cilnidipine
CilnidipineCilnidipine
Cilnidipine
 
Diuretics
Diuretics Diuretics
Diuretics
 
Antidiabetic agents-medicinal chemistry
Antidiabetic agents-medicinal chemistryAntidiabetic agents-medicinal chemistry
Antidiabetic agents-medicinal chemistry
 
H1 and h2 receptor antagonist
H1 and h2 receptor antagonistH1 and h2 receptor antagonist
H1 and h2 receptor antagonist
 

Ähnlich wie API Ingredients

Hospital Pharmacy Isolator Solutions for USP <797> Compliance from Esco
Hospital Pharmacy Isolator Solutions for USP <797> Compliance from EscoHospital Pharmacy Isolator Solutions for USP <797> Compliance from Esco
Hospital Pharmacy Isolator Solutions for USP <797> Compliance from Esco
Esco Group
 
pharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdf
pharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdfpharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdf
pharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdf
AngelitaOrate1
 
Safety alerts for human medical products dialysate concentrates used in hem...
Safety alerts for human medical products   dialysate concentrates used in hem...Safety alerts for human medical products   dialysate concentrates used in hem...
Safety alerts for human medical products dialysate concentrates used in hem...
Michael J. Evans
 

Ähnlich wie API Ingredients (20)

Eli lilly and company
Eli lilly and companyEli lilly and company
Eli lilly and company
 
DICLOFENAC.pptx
DICLOFENAC.pptxDICLOFENAC.pptx
DICLOFENAC.pptx
 
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringeAguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
 
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringeAguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
Aguettant launches the first Sulfite Free EPINEPHRINE plastic Pre-Filled syringe
 
Hospital Pharmacy Isolator Solutions for USP <797> Compliance from Esco
Hospital Pharmacy Isolator Solutions for USP <797> Compliance from EscoHospital Pharmacy Isolator Solutions for USP <797> Compliance from Esco
Hospital Pharmacy Isolator Solutions for USP <797> Compliance from Esco
 
Pharmaceutical industry and unit process
Pharmaceutical industry and unit processPharmaceutical industry and unit process
Pharmaceutical industry and unit process
 
pharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdf
pharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdfpharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdf
pharmaceuticalindustryndunitprocess-150820080148-lva1-app6891.pdf
 
Manufacture of parenteral products and troubleshooting
Manufacture of parenteral products and troubleshootingManufacture of parenteral products and troubleshooting
Manufacture of parenteral products and troubleshooting
 
Manufacture of Parenteral Products and Troubleshooting - Part A
Manufacture of Parenteral Products and Troubleshooting - Part AManufacture of Parenteral Products and Troubleshooting - Part A
Manufacture of Parenteral Products and Troubleshooting - Part A
 
anticoagulant.pptx
anticoagulant.pptxanticoagulant.pptx
anticoagulant.pptx
 
Oral Anticoagulation
Oral AnticoagulationOral Anticoagulation
Oral Anticoagulation
 
Development and in vitro characterization of HIV drugs combination
Development and in vitro characterization of HIV drugs combinationDevelopment and in vitro characterization of HIV drugs combination
Development and in vitro characterization of HIV drugs combination
 
M100700053 shivani kakria
M100700053 shivani kakriaM100700053 shivani kakria
M100700053 shivani kakria
 
M100700053 shivani kakria
M100700053 shivani kakriaM100700053 shivani kakria
M100700053 shivani kakria
 
Cardiotonics
CardiotonicsCardiotonics
Cardiotonics
 
Uses and side-effects of Nebivolol Hydrochloride
Uses and side-effects of Nebivolol HydrochlorideUses and side-effects of Nebivolol Hydrochloride
Uses and side-effects of Nebivolol Hydrochloride
 
Combination Therapy for Glaucoma Management (1).pptx
Combination Therapy for Glaucoma Management (1).pptxCombination Therapy for Glaucoma Management (1).pptx
Combination Therapy for Glaucoma Management (1).pptx
 
Safety alerts for human medical products dialysate concentrates used in hem...
Safety alerts for human medical products   dialysate concentrates used in hem...Safety alerts for human medical products   dialysate concentrates used in hem...
Safety alerts for human medical products dialysate concentrates used in hem...
 
Pharmacovigilance AN
Pharmacovigilance ANPharmacovigilance AN
Pharmacovigilance AN
 
Fastest-Growing Industry of Pharmaceutical.
Fastest-Growing Industry of Pharmaceutical. Fastest-Growing Industry of Pharmaceutical.
Fastest-Growing Industry of Pharmaceutical.
 

Mehr von Sangidha Jagatheesan (9)

Methods to Set Goals and Achieve Them
Methods to Set Goals and Achieve ThemMethods to Set Goals and Achieve Them
Methods to Set Goals and Achieve Them
 
Thermodynamics Chapter 1 (Introduction)
Thermodynamics Chapter 1 (Introduction)Thermodynamics Chapter 1 (Introduction)
Thermodynamics Chapter 1 (Introduction)
 
Presentation 11th april
Presentation 11th aprilPresentation 11th april
Presentation 11th april
 
Etnik presentation
Etnik presentationEtnik presentation
Etnik presentation
 
Family Issues
Family IssuesFamily Issues
Family Issues
 
Paper and Pulp Industry
Paper and Pulp IndustryPaper and Pulp Industry
Paper and Pulp Industry
 
Environmental Science slides
Environmental Science slidesEnvironmental Science slides
Environmental Science slides
 
0.1 introduction to waves
0.1 introduction to waves0.1 introduction to waves
0.1 introduction to waves
 
Chapter 1 introduction to organic chemistry
Chapter 1 introduction to organic chemistryChapter 1 introduction to organic chemistry
Chapter 1 introduction to organic chemistry
 

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 
Interdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptxInterdisciplinary_Insights_Data_Collection_Methods.pptx
Interdisciplinary_Insights_Data_Collection_Methods.pptx
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the Classroom
 
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
 

API Ingredients

  • 2. CONTENTS  Introduction  History  Structure of Carvedilol  Properties of Carvedilol  Uses of Carvedilol  How its‟s works ??  Why Carvedilol is preferred ??  Common Side Effects  Manufacturing Process  SHE Considerations  Price aspect  Market Demand Vs. Supply
  • 3. INTRODUCTION Carvedilol also known as Coreg Used commonly in the treatment of CHF or Congestive Heart failure or high blood pressure Carvedilol is a nonselective beta blocker/alpha-1 blocker indicated in the treatment of mild to severe congestive heart failure (CHF)
  • 4. HISTORY Carvedilol was discovered by Robert R. Ruffolo The discovery and development of carvedilol encountered an adverse regulatory climate, skepticism by the cardiology community and hesitance by the company, and in the early 1990s The fate of the drug was uncertain
  • 5.  Robert R Ruffolo was President of Research and Development for Wyeth Pharmaceuticals, and corporate Senior Vice President of Wyeth from 2001 to 2008 Robert R Ruffolo
  • 7.  The trade name of Carvedilol is known as Coreg  This tablet is oval in shape and white colored  It contains differing concentrations of Carvedilol namely in 3.125, 6.25, 12.5 and 25 m dosages.  Molecular Formula: C 24 H 26 N 2 O 4 Carvedilol in tablet form
  • 8. PROPERTIES OF “CARVEDILOL” These active pharmaceutical ingredients can be dissolved in water, intestinal fluids or gastric fluids Carvedilol should be taken with food
  • 9. USES OF “CARVEDILOL” Carvedilol is used for treating high blood pressure and congestive heart failure. It is also used after a heart attack to improve the chance of survival if your heart is not pumping well To treat a certain type of irregular heartbeat Carvedilol also helps to relax blood vessels, reduces the need for oxygen in the body, and helping the heart beat more regularly and efficiently
  • 10. HOW IT WORKS ?? Most norepinephrine reactants will activate nerve endings, which control heart muscle movements Carvedilol drug works by blocking the binding of the norepinephrine to these receptors  This way, the heart rhythm slows down and the pumping force of the heart muscles is also reduced
  • 11. WHY “CARVEDILOL” IS PREFERRED?? Carvedilol does not worsen existing heart failure symptoms like some other drugs do Compared to other drugs, which work in a similar fashion, Carvedilol does not have much inotropic effects or inverse agonist effects However, there is no scientific evidence to support the fact that Carvedilol is more preferred compared to other beta blocking drugs
  • 12. COMMON SIDE EFFECTS: The most common side effects include: Dizziness Fatigue Hypotension Diarrhea Weight gain
  • 13. SIDE EFFECTS IF YOU DISCONTINUE THE CONSUMPTION OF „CARVEDILOL‟ Sharp chest pain Irregular heartbeat Sometimes heart attack
  • 14. MANUFACTURING PROCESS OF “CARVEDILOL” The manufacture of products based on small molecule Active Pharmaceutical Ingredients (API) remains critical to global healthcare  The manufacturing landscape is also full of challenges and opportunities This is due to emerging international markets and rapidly evolving social, economic, regulatory and environmental expectations
  • 15. SIFTING Sift Carvedilol through , Lactose monohydrate and Ferric Oxide through the above sifted Carvedilol and Lactose monohydrate it is sifted with Ferric Oxide through Lactose monohydrate and Microcrystalline Cellulose.
  • 16. DRY MIXING Load the above sifted material in Rapid mixer granulator and mix for 10 minutes with impeller slow speed. GRANULATING  Add binder solution over dry mix material in a period of 10 minutes at impeller slow speed and mix the content in Rapid Mixer Granulator at impeller slow speed.
  • 17. DRYING Air dry the wet mass for 10 minutes and dry at inlet temperature to reach NMT 80°C, dry the granules till loss on drying reaches to not more than 105°C.
  • 18. SIFTING AND MILLING Sift the dried granules and mill retentions through multimill using 1mm screen at medium speed and knives forward configuration. Sifting of extra granular Materials; Sift Silica Colloidal Anhydrous and Magnesium Stearate.
  • 19. BLENDING AND LUBRICATION  Mix the materials of dried granules with Silica Colloidal Anhydrous in Octagonal Blender for 15 minutes. Add Magnesium Stearate to the above materials in Octagonal Blender for 5 minutes.
  • 23. SAFETY CONSIDERATION  Reduce direct skin contact, reduce exposure via inhalation; and minimize the possibility of chemicals being brought home on workers‟ clothing  As with all potentially hazardous exposures, protective measures should include: engineering controls (e.g., barriers and containments, laboratory hoods, glove boxes, and worker isolation);  Administrative controls; personal protective equipment (e.g., respirators, gloves and lab coats)  Training
  • 24. HEALTH CONSIDERATION Hazardous exposure to workers may occur through inhalation of dust created during: hand manipulation operation of a tablet encapsulation machine by performing sieving and granulation operations
  • 25. PRICE ASPECT OF THIS PROCESS  Chronic heart failure (CHF) is now recognized as a major and escalating public health problem.  The costs of this syndrome, both in economic and personal terms, are considerable.  The prevalence of CHF is 1–2% and appears to be increasing, in part because of ageing of the population.  60 tablets of carvedilol of 25mg would be $4.00
  • 26. MARKET DEMAND VS. SUPPLY  Manufacture and market Carvedilol Tablets, 3.125 mg, 6.25 mg, 12.5, and 25 mg. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Coreg® Tablets, 3.125 mg, 6.25 mg, 12.5 mg, and 25 mg, respectively.  Total annual market sales for Carvedilol Tablets were $1.6 billion (IMS – MAT: June 2007).
  • 27.